White House Moves to Deregulate Unapproved Peptides Despite Safety Warnings

Key points

• On Oct. 14, a temporary 'access policy' appeared on a White House docket, proposing to allow licensed pharmacies to sell unapproved peptides, including BPC-157, TB-500, and MOTS-c.
• FDA scientists advised against the measure in July, citing a lack of clinical trials and potential risks such as liver damage and allergic reactions.
• An FDA advisory panel, including new appointees with financial stakes in the peptide industry, voted to loosen restrictions, contradicting the scientific advice.
• Health Secretary Robert F. Kennedy Jr. and MAHA leaders have promoted peptides, arguing that FDA restrictions hinder access to beneficial treatments.
• Critics, including pharmaceutical trade groups and medical experts, warn that deregulation will reduce incentives for clinical trials and expose consumers to unvetted drugs.

Background

The debate over peptide regulation has intensified as the Make America Healthy Again (MAHA) movement gains traction. Previous coverage highlighted the growing popularity of experimental peptides among influencers and longevity-focused clinics, despite a lack of FDA approval. The current policy shift represents a significant departure from standard regulatory practices, where drugs must undergo rigorous clinical trials before market access.

How outlets are covering it

USA Today and KFF Health News emphasize the misleading nature of peptide marketing, noting that promoters often claim peptides are 'natural' or 'not drugs' to bypass regulations. They highlight that many new FDA panel members have financial conflicts of interest, such as Haleem Mohammed, who is the chief medical officer of a clinic selling peptides. CNN and Yahoo focus on the human impact, citing specific cases of adverse reactions, including migraines and hospitalizations, among users of BPC-157. They argue that the push for 'medical freedom' masks a profit-driven agenda, with influencers and clinics selling unproven treatments. In contrast, proponents like Gary Brecka and Brigham Buhler argue that peptides are safe and effective, citing anecdotal evidence and large patient numbers without reported adverse events, though they have not provided clinical data to support these claims.

Why it matters

The deregulation of unapproved peptides could set a precedent for bypassing FDA safety standards, potentially exposing millions of Americans to untested drugs. It also risks undermining the clinical trial process, as pharmaceutical companies may be less inclined to invest in rigorous research if unapproved alternatives are easily accessible. This move highlights the tension between patient autonomy and regulatory safety, with significant implications for public health and the integrity of medical science.

What to watch

The FDA has not yet issued a final decision on the proposed policy. If implemented, compounding pharmacies would be able to sell unapproved peptides without the usual safety warnings. The outcome will likely depend on further reviews by the FDA and potential legal challenges from pharmaceutical trade groups and public health advocates. The long-term impact on clinical trial funding and public health outcomes remains uncertain.